US 12,351,648 B2
Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
Gregory A. Demopulos, Seattle, WA (US); and Tineka J. Quinton, Seattle, WA (US)
Assigned to Omeros Corporation, Seattle, WA (US)
Filed by Omeros Corporation, Seattle, WA (US)
Filed on Mar. 5, 2021, as Appl. No. 17/194,054.
Claims priority of provisional application 62/986,566, filed on Mar. 6, 2020.
Claims priority of provisional application 63/008,540, filed on Apr. 10, 2020.
Claims priority of provisional application 63/015,299, filed on Apr. 24, 2020.
Claims priority of provisional application 63/054,298, filed on Jul. 21, 2020.
Claims priority of provisional application 63/062,843, filed on Aug. 7, 2020.
Claims priority of provisional application 63/104,229, filed on Oct. 22, 2020.
Claims priority of provisional application 63/105,637, filed on Oct. 26, 2020.
Claims priority of provisional application 63/140,591, filed on Jan. 22, 2021.
Prior Publication US 2021/0292436 A1, Sep. 23, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 11/00 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 11/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 6 Claims
 
1. A method for improving respiratory function in a human subject suffering from COVID-19 induced acute respiratory distress syndrome (ARDS) wherein said subject requires mechanical ventilation, comprising administering to the subject an amount of a MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof and for a time period sufficient to discontinue the need for mechanical ventilation, wherein the MASP-2 inhibitory monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO:69.